Impact of Deutetrabenazine on Functional Speech and Gait Dynamics in Huntington Disease
Latest Information Update: 03 Jun 2024
At a glance
- Drugs Deutetrabenazine (Primary)
- Indications Chorea; Huntington's disease
- Focus Therapeutic Use
- 18 Apr 2024 Results (n=8) assessing effect of deutetrabenazine on functional speech production and gait dynamics in individuals with Huntingtons Disease presented at the 76th Annual Meeting of the American Academy of Neurology 2024
- 12 Dec 2023 Planned End Date changed from 1 Apr 2024 to 1 Apr 2025.
- 12 Dec 2023 Planned primary completion date changed from 30 Aug 2023 to 30 Aug 2024.